^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Keytruda (pembrolizumab)

    i
    Other names: MK-3475, SCH 900475, 1374853-91-4, ORG 307488, SCH-900475, SCH900475, ORG 307488-0, MK 3475, MK3475
    Company:
    Merck (MSD)
    Drug class:
    PD1 inhibitor
    Related drugs:
    24h
    Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Jun 2025 --> Jun 2026
    Trial completion date • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide)
    24h
    KEYNOTE-B61: Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) (clinicaltrials.gov)
    P2, N=160, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer (clinicaltrials.gov)
    P1, N=56, Recruiting, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • First-in-human
    |
    BRAF (B-raf proto-oncogene)
    |
    PD-L1 expression • BRAF mutation
    |
    Keytruda (pembrolizumab) • MQ710
    1d
    Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) (clinicaltrials.gov)
    P3, N=89, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • 5-fluorouracil • epacadostat (INCB024360)
    1d
    Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Obstetrics & Gynecology Hospital of Fudan University
    New P2 trial
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • mirabegron
    1d
    KEYNOTE D46: Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) (clinicaltrials.gov)
    P3, N=614, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    Keytruda (pembrolizumab) • Trodelvy (sacituzumab govitecan-hziy)
    1d
    A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) (clinicaltrials.gov)
    P3, N=160, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab)
    1d
    An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) (clinicaltrials.gov)
    P2, N=267, Active, not recruiting, ModernaTX, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2029 --> Nov 2032 | Trial primary completion date: Sep 2029 --> Nov 2032
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    The cost-effectiveness analysis of immune checkpoint inhibitors for microsatellite instability-high/mismatch repair deficient advanced colorectal cancer. (PubMed, Sci Rep)
    Individual patient data (IPD) from the KEYNOTE-177 and CheckMate-8HW trials were collected with IPDfromKM and used to develop a Markov model with a 30-year duration and three mutually exclusive health states, providing a framework for the evaluation of the cost-effectiveness of first-line nivolumab together with ipilimumab, pembrolizumab, and chemotherapy for treating MSI-H/dMMR advanced CRC. In addition, the established model is stable. First-line immunotherapeutic treatments for MSI-H/dMMR advanced CRC cases in the USA appears to be cost-effective, with a dual-immunotherapeutic regimen consisting of nivolumab plus ipilimumab being preferable.
    Journal • HEOR • Checkpoint inhibition • Mismatch repair • Microsatellite instability • Cost-effectiveness • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC (clinicaltrials.gov)
    P2, N=318, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Initiation date: Jan 2025 --> Jun 2025
    Trial initiation date • Real-world evidence
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed
    1d
    EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Eikon Therapeutics
    New P1/2 trial • Checkpoint inhibition • Mismatch repair • MSI-H • dMMR
    |
    Keytruda (pembrolizumab)
    2d
    Pembrolizumab versus pembrolizumab plus chemotherapy in patients with PDL1 ⩾50% advanced non-small-cell lung cancer, depending on tumor aggressiveness and clinical impact. (PubMed, Ther Adv Med Oncol)
    Pembrolizumab-CT was not associated with improved survival compared with pembrolizumab alone, in PDL1 ⩾ 50% advanced NSCLC patients, even in cases of aggressive disease. Chemotherapy-related toxicities may have had a negative effect on survival.
    Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab)